News & Views
LFD Incorporates Aptamer Reagent for Virus Testing
Aug 17 2020
A collaboration between Aptamer Group and Cytiva, (formerly GE Healthcare Life Sciences), will combine the partners’ expertise in aptamer reagent development with flow technology to produce a Lateral Flow Device (LFD), said to be capable of generating results as a rapid test for COVID-19 infection in less than ten minutes.
The project, which will support scalable non-laboratory testing for virus infections such as COVID-19, highlights the growing prevalence aptamers will take in the process of screening of large numbers of people. Aptamers are synthetic molecules that are made from DNA or RNA that fold into unique three-dimensional structures that allow them to bind to targets with high affinity and high specificity.
The company will retain the intellectual property to its SARS-COVID 2 aptamer and rights to the final product developed by Cytiva.
Dr Arron Tolley, Chief Executive of Aptamer Group said “This collaboration with Cytiva is a significant step forward in the application of aptamers in virus testing. It is also a strong endorsement of the innovation and technology we are applying to help address the global pandemic with an effective, reliable test that delivers quick results. “Once developed, the new test can be deployed to point of care facilities worldwide. We are also looking into the opportunity to develop a home test version, which help increase the opportunity for rapid testing.”
Lee Jenkins, Senior Product Manager at Cytiva added: “We are pleased to support Aptamer Group’s work to develop a COVID-19 point of care diagnostic test. Aptamers are an economical and scalable technology making them very suitable for producing a diagnostic.”
More information online
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan